TE方案与TEC方案对于乳腺癌的化疗效果

2018-11-09 17:49:00黄箕然
上海医药 2018年20期
关键词:乳腺癌

黄箕然

摘 要 目的:比較TE方案与TEC方案对于乳腺癌患者的化疗效果。方法:收集2014年12月至2017至12月赣州上犹县人民医院外科行新辅助化疗的女性乳腺癌患者40例,随机分为观察组和对照组各20例,观察组接受TEC方案,静脉滴注(d1)表柔比星60 mg/m2、多西他赛75 mg/m2、环磷酰胺500 mg/m2;对照组接受TE方案,静脉滴注(d1)表柔比星60 mg/m2、多西他赛75 mg/m2。21 d为1个化疗周期,共进行2~6个周期化疗,连续2个周期后评估疗效。观察两组化疗的短期疗效、化疗期间不良反应以及远期生存情况。结果:观察组总缓解率总缓解率为85%(17/20),对照组为80%(16/20),组间差异无统计学意义(P>0.05)。观察组胃肠道不良反应发生率为80.00%(16/20),显著高于对照组的50.00%(10/20,P<0.05)。两组1年和2年生存率差异无统计学意义(P>0.05),但观察组3年生存率为95%(19/20),显著高于对照组的70%(14/20,P<0.05)。结论:TE方案与TEC方案对乳腺癌的近期化疗效果基本相当,而TEC方案3年生存率更高,但会明显增加胃肠道不良反应。

关键词 乳腺癌;化疗;TE方案;TEC方案;生存率

中图分类号:R737.9 文献标志码:A 文章编号:1006-1533(2018)20-0025-02

Chemotherapy effect of TE and TEC regimens for breast cancer

HUANG Qiran

(Surgical Department of Peoples Hospital of Shangyou County, Ganzhou, Jiangxi 341200, China)

ABSTRACT Objective: To compare the chemotherapy effects of TE and TEC regimens for breast cancer patients. Methods: From December 2014 to December 2017, 40 female breast cancer patients received neoadjuvant chemotherapy in Shangyou Peoples Hospital of Ganzhou were collected and randomly divided into an observation group and a control group with 20 cases each. The observation group received TEC regimen, intravenous drip(d1) epirubicin 60 mg/m2, docetaxel 75 mg/m2, cyclophosphamide 500 mg/m2; the control group received the TE regimen, intravenous drip(d1) epirubicin 60 mg/m2, docetaxel 75 mg/m2. 21 d was a chemotherapy cycle, a total of 2 to 6 cycles of chemotherapy, and the efficacy was evaluated after 2 consecutive cycles. The short-term efficacy of chemotherapy, adverse reactions during chemotherapy, and long-term survival in both groups were observed. Results: The total remission rate of the observation group was 85%(17/20), that of the control group was 80%(16/20), and there was no significant difference between the two groups(P>0.05). The incidence of gastrointestinal adverse reactions of the observation group was 80.00%(16/20), which was significantly higher than that of the control group(50.00%, 10/20, P<0.05). There was no significant difference in 1-year and 2-year survival rates between the two groups(P>0.05). However, the 3-year survival rate of the observation group was 95%(19/20), which was significantly higher than that of the control group 70%(14/20, P<0.05). Conclusion: The TE regimen and the TEC regimen have similar effects on the recent chemotherapy of breast cancer, while the TEC regimen has a higher 3-year survival rate, but it can significantly increase gastrointestinal side effects.

KEY WORDS breast cancer; chemotherapy; TE program; TEC program; survival rate

新辅助化疗是乳腺癌术前常用治疗手段,能够有效缩小肿瘤体积、降低肿瘤分期,为手术治疗提供了良好基础,已成为治疗局部晚期乳腺癌的标准方案[1]。但目前临床上对于乳腺癌术前的新辅助化疗的用药及周期选择并无统一标准,导致医师只能凭经验用药[2]。比较不同新辅助化疗方案的实际疗效有利于为新辅助化疗规范用药提供依据。本文报道采用TE方案和TEC方案治疗乳腺癌的近期和远期疗效,以及两者比较的结果。

1 资料与方法

1.1 一般资料

收集2014年12月至2017年12月赣州上犹县人民医院外科行新辅助化疗的女性乳腺癌患者40例,均符合《中国抗癌协会乳腺癌诊治指南与规范(2015版)》[3]中乳腺癌的诊断标准,并经常规影像学检查结合病理活检确诊。按……

登录APP查看全文

猜你喜欢
乳腺癌
绝经了,是否就离乳腺癌越来越远呢?
中老年保健(2022年6期)2022-08-19 01:41:48
中医治疗乳腺癌的研究进展
乳腺癌的认知及保健
甘肃科技(2020年20期)2020-04-13 00:30:42
乳腺癌是吃出来的吗
胸大更容易得乳腺癌吗
男人也得乳腺癌
防治乳腺癌吃什么:禽比兽好
幸福家庭(2019年14期)2019-01-06 09:15:38
别逗了,乳腺癌可不分男女老少!
祝您健康(2018年5期)2018-05-16 17:10:16
PI3K在复发乳腺癌中的表达及意义
癌症进展(2016年9期)2016-08-22 11:33:20
CD47与乳腺癌相关性的研究进展